MedImmune Deploys Targeted Antibodies In Battle Against Superbugs
Using the ICAAC annual meeting as a platform, MedImmune execs explain efforts to reinvigorate the company’s infectious disease pipeline. Early data suggest a possible supporting role for monoclonal antibody candidates in preventing and treating bacterial infections.
You may also be interested in...
AstraZeneca Straddles The Fence On Antibiotics; Is It About To Fall Off?
The big pharma denies reports it is disbanding antibiotics research, but says it is continuing to explore partnering opportunities for its non-core portfolio, including infectious disease.
Epidemiology First: MedImmune Moving Ahead With Preventive Antibodies, But Needs More HAP Data
The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.
Deals Of The Week Looks At The Intersection Of Patient Empowerment, Generic Drugs And Macaroni & Cheese
Over one-third of practicing physicians cave in to patient requests for a brand-name drug over a generic, but can the trend hold? Also, deals by Baxter/Xenetic, AstraZeneca/FOB, Galectin/SBH, Biogen/UCB and Actavis/Zhejiang Chiral Medicine Chemicals.